Progress report on new antiepileptic drugs A summary of the Second Eilat Conference

J. P. Stables, M. Bialer, S. I. Johannessen, H. J. Kupferberg, R. H. Levy, P. Loiseau, E. Perucca

Research output: Contribution to journalArticle

Abstract

The Second Eilat Conference on New Antiepileptic Drugs was held at the King Solomon's Palace Hotel from October 31 to November 3, 1994. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss new trial designs, drug approval, early use of new antiepileptic drugs, and new drugs in development. Over the last six years, several novel antiepileptic drugs have been introduced worldwide, and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, and vigabatrin. Drugs in development include those at an advanced stage, such as topiramate and tiagabine, as well as those just entering clinical trials, such as remacemide and levetiracetam. The following is a summary of the presentations for drugs in development and newly marketed drugs. The meeting concluded with a presentation, 'Still Searching for the Magic Bullet'.

Original languageEnglish
Pages (from-to)235-246
Number of pages12
JournalEpilepsy Research
Volume22
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Anticonvulsants
etiracetam
felbamate
Pharmaceutical Preparations
Vigabatrin
Drug Approval
Magic
Clinical Trials
Safety

Keywords

  • Antiepileptic drug development
  • Clinical trial design
  • Drug approval

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Stables, J. P., Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., & Perucca, E. (1995). Progress report on new antiepileptic drugs A summary of the Second Eilat Conference. Epilepsy Research, 22(3), 235-246. https://doi.org/10.1016/0920-1211(95)00054-2

Progress report on new antiepileptic drugs A summary of the Second Eilat Conference. / Stables, J. P.; Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Loiseau, P.; Perucca, E.

In: Epilepsy Research, Vol. 22, No. 3, 1995, p. 235-246.

Research output: Contribution to journalArticle

Stables, JP, Bialer, M, Johannessen, SI, Kupferberg, HJ, Levy, RH, Loiseau, P & Perucca, E 1995, 'Progress report on new antiepileptic drugs A summary of the Second Eilat Conference', Epilepsy Research, vol. 22, no. 3, pp. 235-246. https://doi.org/10.1016/0920-1211(95)00054-2
Stables JP, Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P et al. Progress report on new antiepileptic drugs A summary of the Second Eilat Conference. Epilepsy Research. 1995;22(3):235-246. https://doi.org/10.1016/0920-1211(95)00054-2
Stables, J. P. ; Bialer, M. ; Johannessen, S. I. ; Kupferberg, H. J. ; Levy, R. H. ; Loiseau, P. ; Perucca, E. / Progress report on new antiepileptic drugs A summary of the Second Eilat Conference. In: Epilepsy Research. 1995 ; Vol. 22, No. 3. pp. 235-246.
@article{895f1724fe354d64966abb867c958c86,
title = "Progress report on new antiepileptic drugs A summary of the Second Eilat Conference",
abstract = "The Second Eilat Conference on New Antiepileptic Drugs was held at the King Solomon's Palace Hotel from October 31 to November 3, 1994. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss new trial designs, drug approval, early use of new antiepileptic drugs, and new drugs in development. Over the last six years, several novel antiepileptic drugs have been introduced worldwide, and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, and vigabatrin. Drugs in development include those at an advanced stage, such as topiramate and tiagabine, as well as those just entering clinical trials, such as remacemide and levetiracetam. The following is a summary of the presentations for drugs in development and newly marketed drugs. The meeting concluded with a presentation, 'Still Searching for the Magic Bullet'.",
keywords = "Antiepileptic drug development, Clinical trial design, Drug approval",
author = "Stables, {J. P.} and M. Bialer and Johannessen, {S. I.} and Kupferberg, {H. J.} and Levy, {R. H.} and P. Loiseau and E. Perucca",
year = "1995",
doi = "10.1016/0920-1211(95)00054-2",
language = "English",
volume = "22",
pages = "235--246",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Progress report on new antiepileptic drugs A summary of the Second Eilat Conference

AU - Stables, J. P.

AU - Bialer, M.

AU - Johannessen, S. I.

AU - Kupferberg, H. J.

AU - Levy, R. H.

AU - Loiseau, P.

AU - Perucca, E.

PY - 1995

Y1 - 1995

N2 - The Second Eilat Conference on New Antiepileptic Drugs was held at the King Solomon's Palace Hotel from October 31 to November 3, 1994. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss new trial designs, drug approval, early use of new antiepileptic drugs, and new drugs in development. Over the last six years, several novel antiepileptic drugs have been introduced worldwide, and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, and vigabatrin. Drugs in development include those at an advanced stage, such as topiramate and tiagabine, as well as those just entering clinical trials, such as remacemide and levetiracetam. The following is a summary of the presentations for drugs in development and newly marketed drugs. The meeting concluded with a presentation, 'Still Searching for the Magic Bullet'.

AB - The Second Eilat Conference on New Antiepileptic Drugs was held at the King Solomon's Palace Hotel from October 31 to November 3, 1994. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss new trial designs, drug approval, early use of new antiepileptic drugs, and new drugs in development. Over the last six years, several novel antiepileptic drugs have been introduced worldwide, and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, and vigabatrin. Drugs in development include those at an advanced stage, such as topiramate and tiagabine, as well as those just entering clinical trials, such as remacemide and levetiracetam. The following is a summary of the presentations for drugs in development and newly marketed drugs. The meeting concluded with a presentation, 'Still Searching for the Magic Bullet'.

KW - Antiepileptic drug development

KW - Clinical trial design

KW - Drug approval

UR - http://www.scopus.com/inward/record.url?scp=0028860734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028860734&partnerID=8YFLogxK

U2 - 10.1016/0920-1211(95)00054-2

DO - 10.1016/0920-1211(95)00054-2

M3 - Article

C2 - 8991791

AN - SCOPUS:0028860734

VL - 22

SP - 235

EP - 246

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 3

ER -